4565 Sosei Group Corporation

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs).

The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries,’ with Nxera’s NxWave™ platform, a powerful tool for GPCR target selection, validation and structural determination. The partnership aims to bring transformative therapies for multiple diseases of high unmet need. The first project will be aimed at designing antibodies with agonistic function for a challenging GPCR target.

Under the terms of the multi-year agreement, Antiverse will receive an upfront payment and research funding and is eligible for milestone payments. Nxera will retain an exclusive worldwide license to the antibody assets, providing full rights to develop and commercialize the candidates.

Murat Tunaboylu, Co-founder and CEO at Antiverse, said: “Around 220 GPCRs with known disease links are undrugged, and antibodies are an essential tool in our mission to drug them. With Nxera’s expertise and support, we are confident our platform can create antibodies for these particularly challenging targets, bringing us closer to creating life-changing therapies for patients.”

Matt Barnes, EVP, President of Nxera Pharma UK and Head of R&D, said: “Our NxWave™ platform has proven utility in unlocking GPCRs to antibody discovery and combining Nxera’s capabilities with Antiverse’s generative AI antibody design platform enables us to explore this exciting opportunity further, with the aim of developing new biologic therapeutics for multiple diseases, where there is high unmet patient need.”

For Nxera, there is no material financial impact for full year 2024.

–END–

About Nxera Pharma

Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates.

Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit

LinkedIn: | X: | YouTube:

About Antiverse

Antiverse is an artificial intelligence-driven techbio company specialising in antibody design against challenging targets, including G-protein coupled receptors and ion channels. Headquartered in Cardiff, UK and with offices in Boston, USA, and Prague, Czechia, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

Antiverse has collaborated with multiple top global pharmaceutical companies. They are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

To learn more, please visit LinkedIn: | X: | YouTube:

Enquiries:

Nxera – Media and Investor Relations

Kentaro Tahara, VP Investor Relations and Corporate Strategy

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Maya Bennison, Communications Manager

+81 (0)3 5210 3399 | +44 (0)1223 949390 |

MEDiSTRAVA – for International Media

Mark Swallow, Frazer Hall, Erica Hollingsworth

+44 (0)203 928 6900 |

Antiverse - Company Contact and Business Development

Murat Tunaboylu, Co-founder and CEO

Michael Mahdavi, Senior Business Development Manager

9 | |  

Media Relations

Belle Taylor, SomX

Nxera Pharma Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



EN
05/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sosei Group Corporation

 PRESS RELEASE

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following...

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance...

 PRESS RELEASE

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Foll...

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-’568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: ). The US$15 million payment will be fully recognized as revenue in the second qua...

 PRESS RELEASE

Nxera Pharma Achieves Development Milestone in Collaboration with Eli ...

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requir...

 PRESS RELEASE

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data f...

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona. For more information, please read Neuro...

 PRESS RELEASE

Nxera Pharma Operational Highlights and Consolidated Results for the F...

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found . Chris Cargill, President and CEO of Nxera, commented: “As we mark one year since our transformation from Sosei Heptares to Nxera Pharma, I am incredibly proud of the progress we’ve made and how we have evolved. Our new identity has unified the Group and h...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch